Table 1.
ID50-values and DEFs for A549, A549-NTC, A549-920, and NCI-H1975 cells after pretreatment with volasertib (0–10 nM, 24 h), immediately followed by radiotherapy (0–8 Gy). Data are represented as mean ± SD of at least three experiments. DEF > 1 and DEF < 1 indicate radiosensitization and radioresistance, respectively.
| A549 | ID50 | DEF |
|---|---|---|
| 0 nM volasertib → RT | 2.64 ± 0.20 | / |
| 7.5 nM volasertib → RT | 2.02 ± 1.05 | 1.32 ± 0.12 |
| 10 nM volasertib → RT | 0.66 ± 0.07 | 4.07 ± 0.59 |
| A549-NTC | ID50 | DEF |
| 0 nM volasertib → RT | 3.53 ± 0.28 | / |
| 7.5 nM volasertib → RT | 2.26 ± 0.19 | 1.56 ± 0.07 |
| 10 nM volasertib → RT | 1.59 ± 0.25 | 2.24 ± 0.21 |
| A549-920 | ID50 | DEF |
| 0 nM volasertib → RT | 2.45 ± 0.19 | / |
| 7.5 nM volasertib → RT | 1.80 ± 0.61 | 1.44 ± 0.39 |
| 10 nM volasertib → RT | 1.63 ± 0.18 | 1.50 ± 0.07 |
| NCI-H1975 | ID50 | DEF |
| 0 nM volasertib → RT | 1.43 ± 0.04 | / |
| 7.5 nM volasertib → RT | 1.52 ± 0.37 | 0.97 ± 0.26 |
| 10 nM volasertib → RT | 1.48 ± 0.43 | 1.02 ± 0.33 |
ID50-value: radiation dose producing a survival fraction of 50%; DEF: dose enhancement factor; SD: standard deviation; RT: radiotherapy.